Submit Manuscript  

Article Details


Edaravone May Prevent Ferroptosis in ALS

[ Vol. 21 , Issue. 8 ]

Author(s):

Snežana Spasić*, Aleksandra Nikolić-Kokić, Srđan Miletić, Zorana Oreščanin-Dušić, Mihajlo B. Spasić, Duško Blagojević and Zorica Stević   Pages 776 - 780 ( 5 )

Abstract:


Radicava™ (Edaravone) was approved the Food and Drug Administration (FDA) as a new treatment for amyotrophic lateral sclerosis (ALS). Edaravone is a synthetic antioxidant that specifically targets oxidative damage interacting with lipid radicals in the cell. In ALS disease the multiple cell types are involved in devastating loss of motor neurons. Mutations and biochemical changes in various cell types jointly contribute to motor neuron death, disease onset, and disease progression. The overall mechanism of neurodegeneration in ALS is still not completely understood. Dying motor neurons have been reported to exhibit features of apoptosis. However, non-apoptotic features of dying motor neurons have also been reported such as ferroptosis. The role of Edaravone in the prevention of ferroptosis in parallel with other therapeutic approaches to ALS therapy is discussed.

Keywords:

Edaravone, amyotrophic lateral sclerosis (ALS), ferroptosis, therapy, neurons, neurodegeneration.

Affiliation:

Department of Chemistry, Institute of Chemistry, Technology and Metallurgy, National Institute of Republic of Serbia, University of Belgrade, Belgrade, Department of Physiology, Institute for Biological Research "Siniša Stanković", National Institute of Republic of Serbia, University of Belgrade, Belgrade, Department of Chemistry, Institute of Chemistry, Technology and Metallurgy, National Institute of Republic of Serbia, University of Belgrade, Belgrade, Department of Physiology, Institute for Biological Research "Siniša Stanković", National Institute of Republic of Serbia, University of Belgrade, Belgrade, Department of Physiology, Institute for Biological Research "Siniša Stanković", National Institute of Republic of Serbia, University of Belgrade, Belgrade, Department of Physiology, Institute for Biological Research "Siniša Stanković", National Institute of Republic of Serbia, University of Belgrade, Belgrade, Clinic of Neurology, Clinical Center of Serbia, School of Medicine, University of Belgrade, Belgrade



Read Full-Text article